A phase 2 study in 43 relapsed/refractory c-KIT+ AML patients yielded one transient CR (of 2 months duration) and seven PRs (all lasting < 5 months) (Fiedler et al., 2003). The gene discussed is KIT; the disease is acute myeloid leukemia.